A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT06232707 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business objectives have changed

Conditions

Multiple Myeloma

Interventions

DRUG: Alnuctamab
DRUG: Pomalidomide
DRUG: Daratumumab
DRUG: Elotuzumab
DRUG: Carfilzomib
DRUG: Dexamethasone

Sponsor

Celgene